Most Relevant Terms per Topic

Abstracts with Biological Entities (English) - 75 Topics / Sub-Topic Model 71

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5 Topic 6 Topic 7 Topic 8 Topic 9 Topic 10 Topic 11 Topic 12 Topic 13 Topic 14 Topic 15
1 RAS ACE2 expression COVID-19 DPP4 = rats cardiac diabetic ACE-2 amino shedding stroke apod >
2 system ACE mice arbs DPP-4 HF mg/kg heart renal APN lung ADAM17 AT1R HDL de
3 ang enzyme levels aceis agonists sace2 musk failure urinary IV acid pancreatic ischemic binding <
4 angiotensin angiotensin cells sars-cov-2 inhibitors patients PF cardiomyopathy diabetes DPP acute lung injury proximal ischemic stroke PDI [pyr(1)]apelin-13((1–12
5 cardiovascular angiotensin-converting increased infection pparγ activity PH myocarditis diabetic nephropathy aminopeptidase acute tubular cells NGAL PERC pd(2
6 axis kidney stress viral dipeptidyl dogs theaflavin heart failure dialysis peptidases intestinal shed EMMPRIN TCA el
7 II angiotensin ii mrna patients GLP-1 LV administration pompe PRINS meconium gut tubular reperfusion ACE(2 9
8 renin II oxidative mortality dual plasma hepatic dilated nephropathy enzymes B0AT1 ang-(1 MMP-9 strains ±
9 receptor SARS decreased price effects circulating administered death transplant dpp iv ARDS kda infarct LDL los
10 - angiotensin-converting enzyme rat virus I50 sace2 activity BLM structure SONFH AD neutral islets NAP9 ace-inhibitors ECA2
11 ang ii converting protein pandemic side IQR protective effects sars‐cov patients murf2 transporter db/db plaques cgmp [pyr(1)]apelin-13
12 pressure role effect adjustments dpp-4 inhibitors CV EPF dilated cardiomyopathy type 2 diabetes material B(0)AT1 calmodulin ischemia binding site pk(i
13 hypertension 2 overexpression ARB dpp4i CKD3 liver replacement ESRD online acute respiratory distress syndrome ACE2 matrix liquorice 0.06
14 effects expression hearts blockers side effects aps weeks congestive heart failure smad7 authorized distress mitochondrial monocytes rass angiotensina
15 therapeutic homologue oxidative stress % compounds pg/ml insulin resistance congestive MHC version dietary media diminazene affinity xcace
16 7 human cardiomyocytes disease treating CHD dose myocardial care online version influenza β-cell biomarkers lipoproteins apelin-13(f13a
17 review carboxypeptidase macrophages covid-19 infection linagliptin OSA muskrat cardiac hypertrophy apo adenocarcinoma collectrin ectodomain 7)-mas pain =
18 role angiotensin-converting enzyme 2 vascular price adjustments autophagy % insulin DIZE apo d SUPPLEMENTARY intestine mouse HD toxicokinetics potency
19 brain active MI complications drugs 5 group rbcv renoprotective egfr disorder fragments carotid formula xenopus
20 diseases substrate associated with drugs cardiometabolic HFPEF TIIA GAA mutation HSP-60 uptake assay NAPSC parachloromercuribenzoate rodent
21 recent protein in vitro CKD oxldl compared resistance aav6-hserca2a class gliadin hartnup lysates adhesion T24 mammals
22 mas soluble mouse risk peptidase-4 CONCLUSIONS induced B38-CAP pancreas supplementary hypouricaemia infused stage antihyperalgesic silico
23 blood activity losartan infected μm < diet hypertrophy non-diabetic diabetic cardiomyopathy injury d-glucose plaque natriuretic in silico
24 actions data serum severe HDMPPA association fat acute myocarditis portal hypertension aminopeptidase n acids mitophagy ace2-ang-(1 lipoprotein mediante
25 studies surface transgenic syndrome KME 0.0001 oral hserca2a type pic H7N9 pancreatic islets atherosclerosis ANP enzima
26 components zinc significantly off-patent inhibitor measured PRE pompe disease end-stage SK SLC6A19 T2DM logistic termed en
27 renin-angiotensin expressed P2Y(2)R AKI cholesterol levels adipose tissue sudden western activities transport disintegrin cytokine sterol SRAA
28 mechanisms demonstrate IRS-1 diabetes EC BACKGROUND livers rabbit GDM members influenza a - cytokines toxicodynamics apelin-17
29 cardiovascular disease acute respiratory syndrome injury trend AP-W 0.001 NAFLD enzyme replacement therapy microvascular bronchoalveolar small intestine 7 LPS ace2 receptors vertebrates
30 pulmonary generate observed long-term selective participants HFD hypertrophic 4-HNE murf2−/− exercise method leukocytes density 0.04
31 roles site cardiomyocyte coronavirus dipeptidyl peptidase 4 OB high-fat dysfunction prednisone-use pparγ1 form native infarct size variability conserved
32 function substrates FEB antihypertensive molecular − tgf-β1 cardiac function renal transplant hsp90 small pkc-δ ss-induced forebrain putative
33 disease 1–7 protein expression acei AP-N MACE wistar therapy urate gas respiratory miro1 ifn‐β partial ace2s
34 2 act exposed 2007 translation tnfα high-fat diet patient ABCB1 BAL syndrome phorbol 1166C lipids 10,12,13
35 angiotensin-(1 cleavage knockout adjustment dipeptidyl peptidase-4 predictor CCL4 ventricular hcmv-positive hyperoxia microbiota constitutive size nps estudios
36 central appears fibroblasts expenditures core CKD5D b.wt hsβadr1 podocyte MATERIAL 5-HT 619 magnetic spinal seminal
37 discovered vasoconstrictor exposed to renin-angiotensin drugs unique TNFR2 infusion stnx groups ACE-1 transporters no effect CMR proteome sources
38 discuss chloride HGF 2019 proliferator-activated RESULTS orally 3D population hyperoxic l-isoleucine T2D SHR angiotensin-generating 0.17
39 disorders single TI patented thiazolidinediones controls sprague β(1)-ar HSC enkephalins severe immunoreactive VCAM-1 outside-in danio
40 pharmacological cell expressed comorbidities AP-A METHODS hemoglobin infantile-onset national family members acid-supplemented high neuroprotection immobilized nanomolar
41 enzyme recently ang result CD36 CONT dawley immunosuppression stone autism neurogenesis 1 pneumonia deficiency reducción
42 pathologies functions results coronavirus disease 2019 effective diameter bleomycin hypertrophic cardiomyopathy osteonecrosis prolyl membrane-anchored mm anxa1 lipid metabolism se
43 ang 1–7 system reduced cytosolic drug TNFR1 male survivors microvascular thrombosis peptidase distal nutrient endothelial dysfunction pancreas non-mammalian
44 focus angiotensin‐converting study risk factors lipid 0.009 model left mhc class ii lung amino acids PKC logistic regression metabolism <3
45 nervous sensitive overexpressing medications incretin quartile sensorimotor infection hcmv-negative < viruses 7)/masr analyze disulfide promoters
46 therapies converts suppressed GBD2013 glucagon-like cv disease body weight resolution women serum luminal phenylalanine activators microglia exploration
47 angiotensin peptides sites exhibited older ppars median doses serca2a high-salt transcription factors 2009 glucose-induced post-stroke appraises ace-related
48 understood kidney disease compared sars-cov benefit EF occlusion ways rosiglitazone aβ tryptophan β-cells A1166C GC-A making
49 effector cell surface cardiomyocyte hypertrophy sars-cov-2 infection metabolism independent hepg2 rhythm apob bronchial identified fluids small-vessel exemplified 0.0005
50 knowledge domain fibrosis chronic inhibition increased streptozotocin surflex-dock rs1045642 CO(2 aspiration biological fluids ICAM-1 subspecies tetraodon